2026 Appropriations Act: Key Health Policy Changes

Zack Friend, Health Policy Manager

The 2026 Consolidated Appropriations Act (CAA) includes a substantial set of healthcare policy changes that will shape federal health programs, drug pricing oversight, and public health initiatives for years to come. Division F of the legislation contains dozens of provisions affecting Medicaid, Medicare, telehealth policy, prescription drug pricing, and regulatory authorities within the Food and Drug Administration (FDA).

Because the legislation spans hundreds of pages, healthcare stakeholders often rely on concise analyses to understand how the provisions will affect federal programs and the healthcare industry. The memo accompanying this article provides a section-by-section analysis of the major health provisions included in Division F, offering policymakers, providers, and industry leaders a practical reference for navigating the law.
This article provides an overview of the most significant provisions and policy trends included in the legislation. Readers seeking a deeper dive can review the full memo analysis here.

Overview of the Health Package

The health provisions in the 2026 appropriations law are organized across several major policy categories:

Medicaid program updates
Medicare payment and coverage reforms
Public health program extensions
FDA regulatory authorities and pediatric drug development
Prescription drug pricing and pharmacy benefit manager (PBM) oversight

Many of these provisions extend programs that Congress routinely reauthorizes, while others introduce structural reforms intended to increase transparency, improve access to care, and encourage innovation in medical research.

These provisions also build on several existing federal health policies, including the Medicare program and broader reforms affecting healthcare coverage and delivery.

Read More